Automated Analysis of Proliferating Cells Spatial Organisation Predicts Prognosis in Lung Neuroendocrine Neoplasms.
Ki-67
histopathology
lung cancer
lung neuroendocrine neoplasms
machine learning
prognosis
whole-slide image
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Sep 2021
29 Sep 2021
Historique:
received:
24
06
2021
revised:
09
08
2021
accepted:
23
09
2021
entrez:
13
10
2021
pubmed:
14
10
2021
medline:
14
10
2021
Statut:
epublish
Résumé
Lung neuroendocrine neoplasms (lung NENs) are categorised by morphology, defining a classification sometimes unable to reflect ultimate clinical outcome. Subjectivity and poor reproducibility characterise diagnosis and prognosis assessment of all NENs. Here, we propose a machine learning framework for tumour prognosis assessment based on a quantitative, automated and repeatable evaluation of the spatial distribution of cells immunohistochemically positive for the proliferation marker Ki-67, performed on the entire extent of high-resolution whole slide images. Combining features from the fields of graph theory, fractality analysis, stochastic geometry and information theory, we describe the topology of replicating cells and predict prognosis in a histology-independent way. We demonstrate how our approach outperforms the well-recognised prognostic role of Ki-67 Labelling Index on a multi-centre dataset comprising the most controversial lung NENs. Moreover, we show that our system identifies arrangement patterns in the cells positive for Ki-67 that appear independently of tumour subtyping. Strikingly, the subset of these features whose presence is also independent of the value of the Labelling Index and the density of Ki-67-positive cells prove to be especially relevant in discerning prognostic classes. These findings disclose a possible path for the future of grading and classification of NENs.
Identifiants
pubmed: 34638359
pii: cancers13194875
doi: 10.3390/cancers13194875
pmc: PMC8508355
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Pathol. 2017 Mar;241(4):488-500
pubmed: 27873319
J Thorac Oncol. 2019 Sep;14(9):1583-1593
pubmed: 31121325
Virchows Arch. 2019 Sep;475(3):325-334
pubmed: 31201506
Mod Pathol. 2018 Dec;31(12):1770-1786
pubmed: 30140036
Nat Commun. 2019 Aug 20;10(1):3407
pubmed: 31431620
PLoS One. 2011;6(9):e24796
pubmed: 21931854
Virchows Arch. 2017 Feb;470(2):153-164
pubmed: 28054150
J Thorac Oncol. 2019 Sep;14(9):1651-1661
pubmed: 31085341
Arch Pathol Lab Med. 2020 Jan 16;:
pubmed: 31944862
Nat Commun. 2018 Mar 13;9(1):1048
pubmed: 29535388
Histopathology. 2020 Sep;77(3):471-480
pubmed: 32578891
J Thorac Oncol. 2014 Nov;9(11):1656-61
pubmed: 25144243
Histol Histopathol. 2017 Mar;32(3):223-241
pubmed: 27628949
Neuroendocrinology. 2019;108(2):109-120
pubmed: 30485860
Oncotarget. 2016 Jul 5;7(27):41959-41973
pubmed: 27259241
Neuroendocrinology. 2021;111(1-2):158-169
pubmed: 32015233
PLoS One. 2019 Feb 20;14(2):e0212309
pubmed: 30785924
Transl Lung Cancer Res. 2017 Oct;6(5):513-529
pubmed: 29114468
Neuroendocrinology. 2020;110(5):393-403
pubmed: 31422400
Clin Cancer Res. 2016 Jul 15;22(14):3618-29
pubmed: 26960398
Virchows Arch. 2015 Nov;467(5):543-50
pubmed: 26384025
Am J Surg Pathol. 2011 Jun;35(6):853-60
pubmed: 21566513
Front Bioeng Biotechnol. 2019 Oct 01;7:226
pubmed: 31632956
J Pathol Inform. 2019 Mar 08;10:8
pubmed: 30984468
Pathology. 2019 Dec;51(7):681-687
pubmed: 31630876
Pathology. 2019 Aug;51(5):481-486
pubmed: 31230818
Virchows Arch. 2013 May;462(5):507-13
pubmed: 23559305
Semin Oncol. 2018 Aug;45(4):249-258
pubmed: 30348533
Virchows Arch. 2017 Dec;471(6):713-720
pubmed: 28631159
Am J Surg Pathol. 2017 Feb;41(2):263-270
pubmed: 27879513
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
Appl Immunohistochem Mol Morphol. 2019 Nov/Dec;27(10):732-739
pubmed: 31460869
Endocr Relat Cancer. 2013 Dec 16;21(1):1-16
pubmed: 24344249
Int J Surg Pathol. 2020 May;28(3):273-279
pubmed: 31771372